Hyphens Pharma to launch Maruho’s shingles drug in ASEAN

It will commercialise Amenalief® Tab 200mg in 10 ASEAN countries.

Japan-based pharma company Maruho has granted Hyphens Pharma the exclusive rights to register and commercialise shingles treatment, Amenalief® Tab 200mg, in 10 ASEAN countries.

The drug received approval and was launched in Japan in 2017.

In Singapore, more than 90% of adults over 50 carry Varicella-Zoster Virus type 2 (VZV2), putting older individuals at a higher risk of developing shingles.

Hyphens Pharma said Maruho's medication "has a novel mechanism of action that inhibits the proliferation of VZV by inhibiting the activity of the helicase-primase complex, which is essential for viral DNA replication."

"Amenalief® has proven to be effective against VZV when administered once a day for seven days, versus standard therapies that require either three or five times dosing per day. Unlike other oral therapies, Amenalief® does not require any dosage adjustment in patients with renal impairment, a common concern in older patients," Hyphens Pharma said in a bourse filing.

Also Read

Singaporeans' physical well-being at highest level since 2019

SingHealth partners with OutcomesAI to integrate AI into medical workflows

Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

I want to download the media kit